| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_658df3b9d24eb5224b37aaf605741db6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1796
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-50 |
| filingDate |
2020-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e01b7888274f0b3c3d03e26e8415a164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3f66b1502c0234aceb40a0fa3433f22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcbaf0d8ff1a66ae5d8442e841847a70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a0e2a81699ffd2c0f10f3085f120b1c |
| publicationDate |
2020-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020360530-A1 |
| titleOfInvention |
Fgf21 c-terminal peptide optimization |
| abstract |
Disclosed herein are modified C-terminal fragments of FGF21 optimized for binding to Klotho β or antagonizing FGF21 activity. FGF21 peptides modified to comprise modifications to the C-terminal amino acid sequence are disclosed that have enhanced activity at the FGF21 receptor. Additionally, conjugates formed between the optimized FGF21 peptide fragments and insulin like peptides or nuclear hormone receptor ligands are provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11510990-B2 |
| priorityDate |
2016-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |